Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (FACT2)

This study has been withdrawn prior to enrollment.
(Expected inability to recruit study participants in a reasonable amount of time.)
Sponsor:
Information provided by (Responsible Party):
OXiGENE
ClinicalTrials.gov Identifier:
NCT01701349
First received: October 2, 2012
Last updated: April 30, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)